Bloody diarrhea is a common condition in dogs, but studies evaluating the enteropathogens involved specifically in adult dogs are scarce. In the present study, stool samples from 45 adult dogs with bloody diarrhea were evaluated for the four enteric organisms mainly reported in these cases: canine parvovirus type 2 (CPV-2), Clostridioides difficile, Clostridium perfringens, and Salmonella spp. In addition, the samples were also tested for coronavirus, rotavirus, Giardia spp., and Escherichia coli pathotypes to provide a better understanding of possible co-occurrence. Vaccination status, diet, and clinical outcome were also obtained when available. CPV-2b was identified in 17 dogs (37.8%), being the most frequent cause of bloody diarrhea, including completely vaccinated adult dogs. Toxigenic C. difficile and C. perfringens netF were detected in 6 (13.3%) and 5 (11.1%) dogs, in some cases in a co-occurrence with other enteric organisms. Three fatal cases of salmonellosis were identified in dogs fed a raw meat-based diet, raising the risks associated with this increasing practice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tcam.2021.100549DOI Listing

Publication Analysis

Top Keywords

bloody diarrhea
16
enteric organisms
12
adult dogs
12
dogs
8
dogs bloody
8
identified dogs
8
organisms detected
4
detected feces
4
feces dogs
4
bloody
4

Similar Publications

Ischemic colitis (IC) is a multifaceted condition that often manifests with nonspecific symptoms such as abdominal pain and bloody diarrhea, particularly in older adults with vascular risk factors. Diagnosis is supported by elevated levels of white blood cells, lactate, and C-reactive protein (CRP). Computed tomography (CT) imaging typically reveals wall thickening and fat stranding in watershed areas.

View Article and Find Full Text PDF

Objective: To determine the prevalence of amoebiasis, which has been neglected in recent years according to the World Health Organization, in ulcerative colitis patients and investigate the relationship between amoebiasis and ulcerative colitis.

Methods: The study included 150 individuals, including 100 ulcerative colitis patients and 50 healthy individuals without gastrointestinal complaints. The samples collected were first analyzed macroscopically and then using native-Lugol, trichrome staining, and enzyme-linked immunosorbent assay (ELISA).

View Article and Find Full Text PDF

Background: Inflammatory bowel disease (IBD) is a rare adverse effect linked to secukinumab, with limited clinical data available. This study aimed to analyze the clinical features of secukinumab-induced IBD and to offer recommendations for the careful administration of secukinumab.

Methods: We conducted a retrospective analysis by gathering case reports and case series of secukinumab-induced IBD through a database search, with data collected until September 30, 2024.

View Article and Find Full Text PDF

Treatment of immune checkpoint inhibitor-related colitis: a narrative review.

Transl Cancer Res

December 2024

Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background And Objective: Cancer is one of the most difficult diseases facing modern medicine, and increasing amounts of research and clinical treatments are being applied to the treatment of cancer. Immunotherapy, particularly immune checkpoint inhibitor (ICI) therapy, has revolutionized the treatment and overall survival of patients with several different types of cancer. Approximately one-third of patients treated with ICIs may experience immune-related adverse events (irAEs).

View Article and Find Full Text PDF

Paradoxical reactions (PRs) to biologic medications, such as psoriasis, arthritis, and inflammatory bowel disease (IBD), have been increasingly recognized. The aim of reporting this case is to establish an association between golimumab and exacerbation or new (de novo) IBD in patients with axial spondyloarthritis (SpA). Our case involves a young patient with juvenile-onset ankylosing spondylitis (AS) who developed de novo IBD following golimumab therapy for active spinal disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!